^
No biomarker
Burkitt Lymphoma
cyclophosphamide
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
rituximab
Sensitive
:
A1
CD20 positive
Burkitt Lymphoma
rituximab
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
CODOX-M + rituximab
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
R-CVAD
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
R-CVAD + cytarabine + methotrexate
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
EPOCH-R
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
RGDP
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
RICE
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
RIVAC + methotrexate
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
RIVAC
Sensitive
:
A2
No biomarker
Burkitt Lymphoma
RICE + methotrexate
Sensitive
:
A2
LDH elevation
Burkitt Lymphoma
ViPOR
Sensitive
:
C3
TP53 T175H + PIK3CA H1047R
Burkitt Lymphoma
cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone
Sensitive
:
C4
TP53 T175H + PIK3CA H1047R
Burkitt Lymphoma
idelalisib
Sensitive
:
C4
TP53 A159V
Burkitt Lymphoma
PZ01
Sensitive
:
C4
CD19 positive + CD20 positive
Burkitt Lymphoma
rituximab + FT596
Sensitive
:
D
LY9 expression
Burkitt Lymphoma
T-lymphocyte cell therapy
Sensitive
:
D